BioNTech's Changing of the Guard: A Founder Steps Back as the COVID Windfall Fades

BioNTech slashes 2025 revenue guidance, posts wider Q2 loss, and announces CEO handover to Guido Oelkers amid pivot to oncology.

The week that just closed will be remembered at BioNTech for reasons that extend well beyond the balance sheet. Between a sharply reduced full-year outlook, second-quarter red ink, and the announcement that co-founder Ugur Sahin will hand over the chief executive's chair within months, the Mainz-based biotech has signaled a decisive break with its pandemic-era identity. The shares, which closed Thursday at 79.15 euros after slipping 0.69 percent, now trade roughly 6 percent beneath their 200-day moving average of 84.17 euros — a level that captures the market's unease as the company pivots from a COVID-19 franchise in decline toward an oncology pipeline that has yet to generate commercial scale.

A Quarter Defined by Absence

The numbers released Tuesday laid bare the scale of the transition. Revenue for the second quarter collapsed to 105.6 million euros from 260.8 million euros in the same period a year earlier — a drop of roughly 60 percent. The net loss widened to 820.8 million euros, compared with a deficit of 190.4 million euros in the prior-year quarter, translating into a diluted loss per share of 3.24 euros. On an adjusted basis, the shortfall came to 562.3 million euros, or 2.22 euros per share.

Part of that deterioration traces back to a one-off that flattered the 2025 comparison: a compensation payment from Pfizer tied to the termination of a joint shingles vaccine program. With that payment no longer in the picture, the year-on-year decline was always going to look steep. But the underlying trend is unmistakable. BioNTech cited weaker-than-expected global demand for COVID-19 vaccines and deferred milestone payments from a licensed-out research program as the reasons behind its revised guidance.

The company now expects full-year revenue of 1.6 billion to 1.9 billion euros, down from a prior range of 2.0 billion to 2.3 billion euros. Adjusted research and development guidance was trimmed to 2.0 billion to 2.3 billion euros, while selling and administrative costs held steady at 700 million to 800 million euros. Consensus estimates have followed suit, with analysts now modeling roughly 1.9 billion euros in 2026 revenue — a decline of about 30 percent year over year — and a loss per share of 5.45 euros.

A Handover at the Helm

The more consequential news concerned succession. BioNTech's supervisory board has appointed Guido Oelkers to the executive board, with the Swedish Orphan Biovitrum chief executive set to take over as chairman of the board no later than February 1, 2027. Oelkers, who more than quadrupled revenue at the Swedish rare-disease specialist over nine years, inherits a company that Sahin himself acknowledged needs different leadership as it shifts toward a more commercially driven model.

"The next phase of this development requires the corresponding leadership capabilities, and I am convinced that we have found them in Guido," Sahin said. The founder, who built BioNTech alongside Özlem Türeci from a Tübingen startup into a global vaccine powerhouse, announced in March his intention to establish a new, independent company focused on next-generation mRNA innovations, drawing on technologies from BioNTech. Türeci will also depart to co-lead that venture, and the search for her successor as chief medical officer is underway.

For institutional investors, the leadership transition adds another layer of uncertainty to an already volatile picture. Envestnet Asset Management liquidated its entire BioNTech position, according to a regulatory filing, while Raiffeisen Bank International maintained its holding of 35,000 shares unchanged. The stock's 30-day annualized volatility stands at 24.9 percent — a metric that speaks to the market's skittishness around the current news flow.

A Fortress Balance Sheet and a Buyback in Motion

What cushions the transition is cash. As of June 30, BioNTech held 16.634 billion euros in liquid assets and securities, including 9.741 billion euros in cash and cash equivalents. That war chest has allowed the company to press ahead with its share repurchase program despite the losses. During the second quarter, BioNTech bought back 1,693,056 American Depositary Shares at an average price of $89.50 — equivalent to 77.85 euros — for a total outlay of roughly 151.6 million euros. The program, authorized for up to $1 billion, runs through May 2027.

The buyback offers a measure of management confidence, even as restructuring takes a human toll. Media reports indicate BioNTech has closed multiple unused or underutilized production sites, leading to substantial job cuts.

Pipeline Progress Amid the Turbulence

On the research front, the company is leaning heavily on Pumitamig, an antibody candidate developed with Bristol Myers Squibb that is now being tested across seven registration-enabling studies under the ROSETTA program. The first half of the year alone saw the launch of five new global studies targeting triple-negative breast cancer, colorectal, gastric, and non-small cell lung cancer. A collaboration payment of 613 million euros from Bristol Myers Squibb is expected to land in the third quarter, which should provide a meaningful boost to second-half results.

Some milestones have slipped into next year, including a Phase III study of Pumitamig in breast cancer in China and a Phase II trial of Gotistobart in prostate cancer. On the regulatory side, there was a bright spot: on July 29, the European Commission granted marketing authorization for the COVID-19 vaccine adapted to the XFG variant, developed with Pfizer, covering all 27 EU member states plus Iceland, Liechtenstein, and Norway. Both companies are already producing the shot "at their own risk" to ensure supply ahead of the respiratory season.

Analysts Hedge Their Bets

Wall Street has responded to the revised outlook with a mix of caution and continued conviction. Morgan Stanley reaffirmed its buy rating on Friday but trimmed its price target from $126 to $119. Citigroup, reacting a day after the earnings release, lowered its target from $130 to $125 while keeping a "Buy" stance. The shares last traded at 79.70 euros, up 0.82 percent on the day, but remain 24.67 percent below their 52-week high of 105.80 euros reached in January — a gap that underscores lingering skepticism about the company's near-term trajectory.

The next milestone for investors arrives on November 3, when BioNTech reports third-quarter results. Between now and then, the market will be watching how the impending leadership change shapes the balance between a shrinking vaccine business and an oncology pipeline that has yet to prove its commercial worth.